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wwwRisk stratiﬁcation in Barrett’s esophagus patients with
diagnoses of indeﬁnite for dysplasia: the deﬁnite silver bullet
has not (yet) been foundAlthough showing some promising results, the
use of biomarkers is not (yet) part of the
guidelines recommended by the GI societies. So
what should we do if we are confronted with a
patient with a diagnosis of IND?In Barrett’s esophagus (BE), both endoscopic surveil-
lance interval and treatment recommendations are based
on the presence and grade of histopathologically diag-
nosed dysplasia, because dysplasia currently best predicts
the risk of progression to esophageal adenocarcinoma
(EAC). Owing to the low risk of progression, periodic
endoscopic surveillance is recommended in nondysplastic
BE (NDBE), whereas a more intensive surveillance or even
preventive ablation can be considered in patients with low-
grade dysplasia (LGD). By contrast, the risk of progression
in BE patients with diagnoses of indeﬁnite for dysplasia
(IND) and as a consequence their further treatment remain
controversial.
In this issue of Gastrointestinal Endoscopy, Krishna-
moorthi et al1 report the results of a systematic review in
which 8 studies originating from both Europe and North
America including a total of 1441 BE patients with a
diagnosis of IND and a reported outcome of high-grade
dysplasia (HGD) and/or EAC were identiﬁed. In the subse-
quent meta-analysis, a pooled incidence rate of HGD, EAC,
or both of 1.5 per 100 person-years and a slightly lower
incidence rate of EAC alone of 0.6 per 100 person-years
were estimated. No substantial differences in incident rates
were found in the subgroup analysis of HGD, EAC, or both
if studies were compared regarding their origin (Europe vs
North America, 1.6 vs 1.4 per 100 person-years, respec-
tively) or study quality (medium vs high, 1.7 vs 1.3).
When progression to EAC alone was analyzed, a signiﬁ-
cantly higher incidence rate of 0.9 versus 0.4 per 100
patient-years was observed if studies from Europe were
compared with those from North America, respectively. A
moderate to substantial heterogeneity of the included
studies was noted in all analyses. The authors conclude a
similar incidence rate of BE-IND and LGD and therefore
recommend an intensiﬁed surveillance program.
However, the complexity behind the term “IND” raises
the question whether the underlying data allow one to
draw an adequate conclusion on how to treat these
patients.
Two fundamental questions have to be adressed in
every systematic review and meta-analysis. First, are theright ª 2020 by the American Society for Gastrointestinal Endoscopy
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.giejournal.orgincluded patient populations homogeneous enough to
be summarized? Second, can the ﬁndings be transferred
to an equal patient population? Both may be questioned
in this report. All included samples were analyzed retro-
spectively, with the majority being collected at tertiary
referral centers. In particular, the second limitation is
highly biased toward an increased progression risk for
IND: Does a patient with a diagnosis of IND in a center
with experienced gastroenterologists and GI pathologists
carry the same progression risk as a patient identiﬁed in
a community hospital (where most BE care is given)?Inasmuch as none of the studies included a pathologist’s
deﬁnition of IND within the methods section, how
should we avoid painting different entities with the
same brush? In addition to differing levels of experience,
this may be another reason for the reported poor inter-
observer agreement among pathologists in diagnosing
IND, and it may partly explain the different progression
risks when studies from Europe and North America are
compared.
Nevertheless, the authors can hardly be critizied for
including a highly varied population of patients with diag-
noses of IND, because this might be a logical consequence
of the vague deﬁnition of the term “IND” itself.
Before 2000, the use of both conventional Western and
Japanese classiﬁcation systems resulted in large interob-
server differences in the diagnosis of GI tumors, mainly
caused by a varying focus on cytologic and architectural
features between Western and Japanese pathologists.
The adoption of the revised Vienna criteria2 created a
uniform 5-tier classiﬁcation system based on a combination
of architectural and cytologic features and invasion
status. All participating pathologists agreed that this classi-
ﬁcation should include the new category “indeﬁnite for
dysplasia” when one cannot decide whether a lesion is
dysplastic.Volume 91, No. 1 : 2020 GASTROINTESTINAL ENDOSCOPY 11
Editorial Frei et alIn nondysplastic biopsy specimens next to a preserved ar-
chitecture, the cytologic aspect appears nearly normal, and
surface maturation can be seen.3 By contrast, LGD
architecture can be slightly altered and surface maturation
is distorted, accompanied by mild but diffuse cytologic
changes, reﬂected by nuclear hyperchromasia and mild to
moderate increase in size and shape (often enlongated but
retaining basal orientation). Logically, in the presence of
preserved architecture and surface maturation but altered
cytologic changes such as increased mitoses in the deeper
glands and mild nuclear atypia, a distinction between
absence or presence of dysplasia might be difﬁcult, and a
diagnosis of IND may be reasonable. Additionally,
inﬂammation and regenerative changes after epithelial
injury can both cause signiﬁcant cellular and nuclear
changes that closely mimic dysplasia. Because in IND,
elements from both reactive nondysplastic changes and
aspects from “true” dysplasia could be present, it is likely
that IND patients constitute a very heterogeneous group
that includes patients without dysplasia but reactive
changes and a very low risk of progression, and patients
with true dysplasia and consecutively higher risk for
progression to cancer.
The experience of a pathologist is one of the key factors in
separating these 2 subgroups. Obviously, the distinction be-
tween these subtle changes is even harder for pathologists
who do not see BE biopsy specimens very frequently. Conse-
quently, a less-experienced pathologists may diagnose IND
rather than reactivenondysplastic changes so asnot tomiss pa-
tients at risk for progression. By contrast, an expert GI pathol-
ogist may be able to identify patients with true dysplastic
changes.With the inclusion of additional patients with reactive
changes into the IND category, the true risk of progression in
IND patients will be diluted. In a similar manner, one would
expect additional patients to receive “overdiagnoses” of LGD
in comparison with the diagnoses applied by a highly experi-
ence GI pathologist. This was shown in a Dutch study
published in 2015, in which 293 patients with a community-
based diagnosis of LGD were reviewed by 3 expert GI pathol-
ogists.4 The majority of patients were downstaged to NDBE
(59%), whereas 14% received diagnoses of IND and 27% had
a conﬁrmed diagnosis of LGD. This resulted in a low risk of
HGD/EAC of 0.6% and 0.9% per patient-year in NDBE and
IND patients, respectively, compared with a signiﬁcantly
increased risk of HGD/EAC of 9.1% per patient-year in
conﬁrmed LGD cases. This study highlights the need for
expert GI pathologist review for a diagnosis of IND. Although
an accepted deﬁnition of the term “expert GI pathologist” is
lacking and the term itself remains vague, the same Dutch
study group developed benchmark criteria for pathologists
who aspire to join a core group of experienced BE patholo-
gists.5 Although this selection may be subjective, a low
number of IND diagnoses was 1 out of a total of 4 criteria.
European guidelines (British Society of Gastroenter-
ology and European Society of Gastrointestinal Endos-
copy) and the American College of Gastroenterology (no12 GASTROINTESTINAL ENDOSCOPY Volume 91, No. 1 : 2020speciﬁc recommendations are made by the American
Gastroenterological Association) slightly differ. All guide-
lines advise repeating the endoscopy after 6 months of
intensiﬁed antireﬂux therapy after a conﬁrmed diagnosis
of IND, similar to the management of conﬁrmed LGD.
The 2 European Guidelines recommend endoscopically
surveying patients with repetitive and expert conﬁrmed
IND similar to NDBE every 3 to 5 years, whereas the Amer-
ican College of Gastroenterology suggests applying the
same annual surveillance interval as in conﬁrmed LGD. In
none of the guidelines is preventive ablative therapy in
the presence of IND recommended.
Although review by an expert pathologist is signiﬁcantly
better than diagnosis by a less-experienced pathologist, it
is still a subjective grading of subtle changes, resulting in
an at best moderate interobserver agreement in patients
with IND or LGD. To complicate matters, some patholo-
gists use IND in slightly different settings, for example, in
the setting of massive inﬂammation where cells can look
highly atypical (resembling HGD) whereas others use it
for mild changes when they cannot decide whether or
not it is sufﬁcient for LGD. Additionally, new sampling
techniques, such as wide-area transepithelial brush sam-
pling, are gaining more interest, and the larger tissue areas
sampled may increase the number of diagnoses with (yet)
“indeﬁnite” signiﬁcance (such as basal crypt dysplasia).6
More objective tools are clearly needed to facilitate risk
stratiﬁcation in patients with IND and LGD. Critchley-
Thorne et al7 combined immunoﬂuorescence-based analysis
of epithelial and stromal biomarker features such as p53,
HER2, COX2, and AMACR with morphologic changes using
an automatized whole slide image analysis algorithm. The re-
sulting 3-tier classiﬁer accuratly risk stratiﬁedNDBE, IND, and
LGD into low risk, intermediate risk, or high risk for progres-
sion toHGD/EAC. This classiﬁer provided independent prog-
nostic information that outperformed the histopathologic
risk prediction based on analysis by a GI expert. Other ap-
proaches based on somatic chromosomal alterations have
also been shown to predict progression independent from
the histopathologic diagnosis of dysplasia. Li et al8 used a
risk prediction model containing 29 somatic chromosomal
alterations that outperformed prediction made by
histopathology and immunohistochemistry. Recent work
suggests that TP53 may be an early event in the cascade to
progression to EAC, which is able to dinstinguish between
BE patients who experience progression and those who do
not.9 Their genomic analysis using formalin-ﬁxed parafﬁn-
embedded tissue blocks demonstrated that almost half of
the patients who experienced progression in their case-
control study had TP53 mutations, whereas such mutations
were found in only 5% of the control individuals who did
not experience progression.
Although showing some promising results, the use of
biomarkers is not (yet) part of the guidelines recommen-
ded by the GI societies. So what should we do if we are
confronted with a patient with a diagnosis of IND?www.giejournal.org
Frei et al EditorialWe likely do not have the tools yet to accurately risk
stratiﬁy these patients, inasmuch as the term “IND” reﬂects
less an accurate diagnosis and more a diagnosis of uncer-
tainty by the pathologist. This diagnostic gap is therefore
an interim step until the true nature of the lesion reveals
itself by either progressing to “true” dysplasia or downstag-
ing to NDBE. Nevertheless, because the limited data that
we have suggest that a minority of the patients with
community-diagnosed IND either already harbor LGD or
will experience progression to LGD, reviewing the initial
diagnosis by an expert pathologist seems to be the most
logical step. If the diagnosis is subsequently downstaged
or upstaged to NDBE or LGD, respectively, the surveillance
interval should follow that diagnosis. In those rare cases in
which the expert review still results in the diagnosis of
IND, repeated endoscopy after 6 months along with inten-
siﬁed antireﬂux therapy to minimize interfering inﬂamma-
tion seems a logical aproach. In the majority of cases, the
true nature of IND (either NDBE or LGD) will then show
its face. Very few patients will have a persistent diagnosis
of IND over the course of multiple surveillance endoscopies.DISCLOSURE
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